Immatics N.v. · NASDAQ:IMTX
Immatics — Technical Presentation (October 2026)
23 slides from Immatics's technical presentation, Oct 23, 2026
Slide 1: Targeting PRAME+ Tumors with IMA203CD8, a PRAME-directed TCR T-cell Therapy: Phase 1 Results
Targeting PRAME+ Tumors with IMA203CD8, a PRAME - directed TCR T - cell Therapy: Results from a Phase 1 Study Antonia Busse 1 , Dejka M. Araujo 2 , Winfried Alsdorf 3 , Oladapo Yeku 4 , Tobias A.W. Holderried 5,6 , Leonel F. Hernandez - Aya 7 , Sarah Taylor 8 , Dirk Jaeger 9 , Manik Chatterjee 10 ,
Slide 2: Declaration of Interests
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 2 Declaration of Interests Prof. Dr. med. Antonia Busse , abstract #7231 Employment or leadership position: None Consultancy/advisory activities: None Ownership of shares, stocks or inves
Slide 3: IMA203CD8: A Systemic TCR T-cell Therapy Targeting PRAME
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 3 IMA203CD8: A Systemic TCR T - cell Therapy Designed to Target the Intracellular Tumor Antigen PRAME Prof. Dr. med. Antonia Busse , abstract #7231 IMA203CD8 is an investigational therapy
Slide 4: Phase 1 Multicenter Trial of IMA203CD8 in PRAME+ Solid Tumors
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 4 Phase 1 Multicenter Trial of IMA203CD8 in PRAME+ Solid Tumors Prof. Dr. med. Antonia Busse , abstract #7231 IMA203 - 101: NCT03686124; Based on initial safety data observed with anzu -
Slide 5: Patient Disposition
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 5 Patient Disposition Prof. Dr. med. Antonia Busse , abstract #7231 Gynecologic indications include ovarian cancer and uterine cancer ; melanoma includes cutaneous , uveal , mucosal , acr
Slide 6: Baseline Characteristics
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 6 Baseline Characteristics Prof. Dr. med. Antonia Busse , abstract #7231 a All patients who started lymphodepletion. b All patients who received IMA203CD8 infusion and had ≥1 postbaseline
Slide 7: Treatment Experience
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 7 Treatment Experience Prof. Dr. med. Antonia Busse , abstract #7231 Efficacy - evaluable Population b Safety Population a On Study Other n=7 Synovial Sarcoma n=12 Melanoma n=44 Gynecolog
Slide 8: Tolerability in Advanced Solid Tumors
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 8 Tolerability in Advanced Solid Tumors Prof. Dr. med. Antonia Busse , abstract #7231 a All patients who started lymphodepletion, including 1 patient who did not receive IMA 203 CD 8 cell
Slide 9: TCR Activity Across Indications
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 9 TCR T - cell Activity Across Indications Prof. Dr. med. Antonia Busse , abstract #7231 % activated TCR T cells is evaluated based on surface expression of PD - 1 (% PD - 1 positive TCR
Slide 10: Best Overall Response by Indication (Waterfall Plot)
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 10 'DWDFXW RII ; D[LV ,QGLFDWLRQ 3RSXODWLRQ ,0$ &' :DWHUIDOO 2QJRLQJ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67
Slide 11: Tumor Reduction Across Dose Levels During Dose Escalation by Indication
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 11 'DWDFXW RII 3DWLHQWVDUHRUGHUHGE\EHVWSHUFHQWDJHFKDQJHZLWKLQHDFKVXEJURXS 6XEJURXSRUGHU 6HOHFWHGVXEJURXSEORFNV :DWHUIDOO3ORW 2QJRLQJ 3' 6'
Slide 12: Changes in Tumor Size Over Time
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 12 Changes in Tumor Size Over Time Prof. Dr. med. Antonia Busse , abstract #7231 BOR, best overall response; (c)CR, (confirmed) complete response; mFU , median follow - up; PD, progressiv
Slide 13: Responses of Metastatic Lesions
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 13 Responses of Metastatic Lesions Prof. Dr. med. Antonia Busse , abstract #7231 Each data point represents reduction of a target lesion . Total number of target lesions evaluated : 241.
Slide 14: Antitumor Activity at Higher Doses in Patients with Gynecologic Indications
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 14 0RQWKVSRVW7FHOOLQIXVLRQ %DVHOLQH >@ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI7DUJHW/HVLRQVIURP 3' %DVHOLQH 35 3' 6' 35 F35 &5 F&5
Slide 15: Durability Potential at Higher Doses in Patients with Gynecologic Indications
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 15 .DSODQ 0HLHUHVWLPDWHV FHQVRULQJLQGLFDWHGE\SOXVVLJQV 'DWDFXW RII 3RSXODWLRQ *\Q2QF%XQGOH ,0$ &' LQ'/ FRUKLJKHULQ($6 3URJUHVVLRQ
Slide 16: Conclusions
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 16 Conclusions Prof. Dr. med. Antonia Busse , abstract #7231 • IMA203CD8 demonstrated a consistent and manageable safety profile in patients with advanced PRAME - positive solid tumors •
Slide 17: Thank You – Trial Participants & Caregivers
Thank You – Trial Participants & Caregivers Prof. Dr. med. Antonia Busse , abstract #7231 This study was funded by Immatics , Inc. Biostatistical and translational support was provided by Friedrich Vollmer, MSc , and Ana Maia, PhD with Immatics , Inc. Medical writing support was provided by Decera C
Slide 18: Appendix
Evo""" Appendix
Slide 19: Patient Disposition
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 19 Patient Disposition Prof. Dr. med. Antonia Busse , abstract #7231 a All patients who started lymphodepletion . b All patients who received IMA203CD8 infusion and had ≥1 postbaseline sc
Slide 20: IMA203CD8 TCR Expansion and Persistence in Multiple Indications
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 20 IMA203CD8 TCR T - cell Expansion and Persistence in Multiple Indications Prof. Dr. med. Antonia Busse , abstract #7231 *n indicates the maximum number of patients contributing to an in
Slide 21: IMA203CD8 TCR Persistence in Peripheral Blood in Multiple Indications
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 21 IMA203CD8 TCR T - cell Persistence in Peripheral Blood in Multiple Indications Prof. Dr. med. Antonia Busse , abstract #7231 Shorter follow - up for gynecologic indications due to late
Slide 22: Patient-level Data in Gynecologic Cancers Treated at ≥DL4c in Phase 1
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 22 Patient - level Data in Gynecologic Cancers Treated with IMA203CD8 at ≥DL4c in Phase 1 (n=20) Prof. Dr. med. Antonia Busse , abstract #7231 N=20 patients in efficacy population include
Slide 23: Patient-level Data in Gynecologic Cancers Treated at ≥DL4c in Phase 1 (continued)
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 23 Patient - level Data in Gynecologic Cancers Treated with IMA203CD8 at ≥DL4c in Phase 1 (n=20) Prof. Dr. med. Antonia Busse , abstract #7231 N=20 patients in efficacy population include